3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
13
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Solid Tumors Harboring a BRAF V600 Mutation
1
Skin Neoplasms
1
Skin Diseases
1
Pancreatic Neoplasms
1
Lymphatic Metastasis
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Astrocytoma
1
Advanced BRAF Mutant Cancers
1
Interventions
aldesleukin
15
Cyclophosphamide
15
fludarabine phosphate
12
fludarabine
11
Interleukin-2
10
Nivolumab
6
Ipilimumab
6
Temozolomide
5
pembrolizumab
3
Fluorouracil
3
trametinib
2
sonidegib
2
dabrafenib
2
binimetinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Sodium Chloride
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Peptides
2
HhAntag691
2
Gefitinib
2
Dacarbazine
2
Cyclosporine
2
Cetuximab
2
Capecitabine
2
veliparib
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Neoplasms
×
encorafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA